Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Adding Healsea® Isotonic Nasal Spray to Conventional Therapies for the Care of Children With Allergic Rhinitis Presenting With Symptoms of Acute Infectious Rhinitis: an Observational Study

NCT05034328 is registered in ClinicalTrials.gov with Lallemand Pharma AG as lead sponsor.

NCT NCT05034328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05034328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Adding Healsea® Isotonic Nasal Spray to Conventional Therapies for the Care of Children With Allergic Rhinitis Presenting With Symptoms of Acute Infectious Rhinitis: an Observational Study
Lead sponsor
Lallemand Pharma AG
Phase
Observational
Overall status
Completed
Start date
February 14, 2022
Completion date
November 3, 2022
Enrollment
186 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

allergy, common cold